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Emergence of SARS-CoV-2 variants may have implications for 
irus transmissibility and immune response, as well as for the vac- 
ination strategy, creating the need to rapidly screen for the pres- 
nce of variants in COVID-19 samples( 1 , 2 ). Among them, much at- 
ention has been paid to the 501Y.V1 (also named B.1.1.7), 501Y.V2 
nd 501Y.V3 (also named P1) variants detected in UK, South Africa 
nd Brazil, respectively( 3 , 4 , 5 ). High throughput sequencing (HTS) 
echnologies represent the gold standard for variantsidentification, 
ut they are resource intensive, require expertise and have a long 
urnaround time(i.e. several days or weeks). 
It is therefore essential to combine the routine genomic surveil- 
ance of SARS-CoV-2 variants with targeted methods such as RT- 
CR that are simpler, more rapid and less expensive to imple- 
ent.Recent PCR-based protocols targeted different mutant regions 
ithin the SARS-CoV-2 genome, in particular ORF1 and Spike 
S) genes. Common mutations (e.g. 3675–3677 in ORF1a gene; 
501Y in S gene) were used to detect all three variants of interest, 
ithout distinction( 6 , 7 , 8 ). Specific detection of some SARS-CoV-2 
ariants were also investigated, using unique mutations or dele- 
ions (e.g. 69/70 HV for UK variant) ( 8 ), but so far no protocol
as been specifically developed for the South African variant. 
To differentiate between501Y.V2and the two other main 
ariants (501Y.V1 and 501Y.V3),literatureexamination and nu- 
leotide alignment of the SARS-CoV-2 reference towardsthe three 
ain variantsgenomes allowedus to design primers flanking the 
pecific 242–244 LLA deletion from the 501Y.V2 spike gene, 
nd a probe that covered the deletion.This strategy, also named 
Table 1 
Primer and probe sequences tested for the proposed SA
variants, RNase P control). 
Set name Nt positions TM Primers/prob
CDC 
N1 
28,287–28,306 53.6 Forward prim
28,335–28,358 57.7 Reverse prim
28,309–28,332 63.3 Probe 
CDC 
N2 
29,164–29,183 52.3 Forward prim
29,213–29,230 54.1 Reverse prim
29,188–29,210 63.2 Probe 
Liege 
242/244del 
22,239–22,261 55.2 Forward prim
22,365–22,387 55.1 Reverse prim
22,274–22,298 53.5 Probe 
Yale 
69/70del 
21,710–21,733 59.3 Forward prim
21,795–21,817 57.4 Reverse prim





63.5 Probe ttps://doi.org/10.1016/j.jinf.2021.04.035 
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Sequence 
GAC CCC AAA ATC AGC GAA AT 
TCT GGT TAC TGC CAG TTG AAT CTG 
FAM- ACC CCG CAT TAC GTT TGG ACC- BHQ1 
TTACAA ACA TTG GCC GCA AA 
GCG CGA CAT TCC GAA 
FAM -ACA ATT TGC CCC CAG CGC TTC AG- BHQ1 
TGG TAG ATT TGC CAA TAG GTA TT 
AAA AGT CCT AGG TTG AAG ATA AC 
ROX -TTT CAA ACT TTA CTT GCT TTA CAT A- BHQ2 
TCA ACT CAG GAC TTG TTC TTA CCT 
TGG TAG GAC AGG GTT ATC AAA C 
Cy5 -TTC CATG CTA TAC ATG TCT CTG GGA- BHQ2 
AGA TTT GGA CCT GCG AGC G 
GAG CGG CTG TCT CCA CAA GT 
HEX -TTC TGA CCT GAA GGC TCT GCG CG- BHQ1 
drop-out”,allowes for amplification and detects all SARS-CoV-2 
iruses that do not contain the deletion, while the South African 
01 V.V2 variant is not amplified. A multiplex RT-qPCR was thus 
eveloped to detect four targets: i) the N1/N2 genes of SARS-CoV- 
; ii) the drop-out approach for 501 V.V2 variant ( 242–244 LLA 
eletion); iii) the drop out approach for 501 V.V1 variant ( 69/70 
V deletion) developed in 8 b); and iv) RNA quality control using 
nase P gene ( Table 1 ). 
The multiplex assay was tested on fifty-eight SARS-CoV-2 sam- 
les: twenty samples belonging to a variety of strains without the 
242–244 LLA and 69/70 HV deletions), twenty samples belong- 
ng to 501Y.V1 lineage( 69/70 HV deletion), eight samples belong- 
ng to the 501Y.V3 lineage, and ten samples belonging to 501Y.V2 
ineage ( 242–244 LLA deletion). All samples were nasal or na- 
opharyngeal swabs, and nucleic acid was extracted from 300 μL 
iral transport medium and eluted in 50μL using the Maxwell®
SC Viral TNA kit (Promega, USA). SARS-CoV-2 lineage was firstly 
etermined by Whole Genome Sequencing using Minion (Oxford 
anopore Technologies, USA)( 9 ). The multiplex RT-qPCR was per- 
ormed in duplicates using the TaqMan TM Fast Virus 1-Step Master 
ix (Applied Biosystems – Life Technologies, USA) with 400 nM of 
ach primer and 200 nM of each probe per reaction, and 5 μL of 
NA in a total reaction volume of 20 μL. PCR cycler conditions were 
everse transcription for 10 min at 55 °C, initial denaturation for 
 min at 95 °C, followed by 45 cycles of 10 s at 95 °C and 1min15
t 55 °C, and a final cooling of 30 s at 40 °C on the LightCycler480
Roche, USA). 
The results showed that our 242/244 del “drop-out”
rimer/probe set can serve as a screening tool to specifically eserved. 
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Table 2 
Validation results of the multiplexed 501 V.V2 variant screening RT-qPCR assay on different SARS-Cov-2 lineages. Cycle threshold values are indicated for the four targets: 
N1/N2 genes, drop-out 242/244 deletion, drop-out 69/70 deletion and the RNase P control. No detection was indicated by “ND”. 
Samples ID SARS-CoV-2 
Lineages 
Detection (Ct values) 
N1/N2 Liege 242/244del Yale 67/70del RNase P 
Liege-1 B.1.351 501 V.V2 
South African variant 
7.78 ND 10.81 31.45 
Liege-2 11.20 ND 14.87 28.82 
Liege-3 12.70 ND 14.28 29.76 
Liege-4 15.31 ND 18.17 26.42 
Liege-5 15.36 ND 19.77 25.33 
Liege-6 16.83 ND 18.08 27.18 
Liege-7 17.42 ND 18.78 28.34 
Liege-8 17.78 ND 19.16 28.11 
Liege-9 22.50 ND 24.87 29.02 
Liege-10 22.86 ND 26.23 23.45 
Liege-11 P1 501 V.V3 
Brazilian variant 
9.17 14.77 12.45 32.14 
Liege-12 9.73 15.22 12.99 32.07 
Liege-13 13.43 18.73 17.21 29.1 
Liege-14 14.17 18.7 16.88 31.58 
Liege-15 14.23 18.59 16.99 27.93 
Liege-16 14.55 20.89 18.63 27.17 
Liege-17 17.23 22.37 20.49 25.93 
Liege-18 18.8 22.05 20.36 31.93 
Liege-19 B.1.1.7 501.V1 
UK variant 
11.69 15.95 ND 34.13 
Liege-20 12.16 15.99 ND 30.79 
Liege-21 12.45 17.35 ND 30.61 
Liege-22 13.53 18.88 ND 22.64 
Liege-23 17.27 19.76 ND 32.81 
Liege-24 17.46 20.80 ND 31.44 
Liege-25 17.60 21.38 ND 26.61 
Liege-26 17.88 20.76 ND 32.63 
Liege-27 18.16 20.51 ND 33.64 
Liege-28 18.96 23.15 ND 25.79 
Liege-29 19.27 22.56 ND 33.81 
Liege-30 19.76 21.72 ND 28.32 
Liege-31 20.37 23.92 ND 31.79 
Liege-32 20.58 25.41 ND 29.82 
Liege-33 21.73 23.53 ND 32.87 
Liege-34 22.31 26.11 ND 27.43 
Liege-35 23.01 27.22 ND 27.32 
Liege-36 23.60 27.62 ND 24.54 
Liege-37 23.84 26.98 ND 26.27 
Liege-38 29.16 33.18 ND 29.60 
Liege-39 B.1.221 10.87 13.84 12.64 26.47 
Liege-40 B.1.221 12.66 15.79 14.49 32.66 
Liege-41 B.1.221 12.82 16.26 15.27 30.33 
Liege-42 B.1.221 13.57 16.33 14.97 26.81 
Liege-43 R.1 13.74 16.95 15.43 31.34 
Liege-44 B.1.214.2 14.18 19.16 16.73 27.58 
Liege-45 B.1.221 15.19 19.06 16.53 34.03 
Liege-46 B.1.221 18.69 21.22 18.81 30.62 
Liege-47 B.1.221 18.75 21.59 18.87 28.73 
Liege-48 B.1.221 19.41 21.95 20.54 33.49 
Liege-49 B.1.221 19.75 22.59 21.55 28.8 
Liege-50 B.1.221 21.29 24.98 22.58 28.77 
Liege-51 B.1.160 21.8 24.17 22.51 29.61 
Liege-52 B.1.221 22.51 26.66 24.53 27.41 
Liege-53 B.1.177 22.98 27.25 24.57 31.07 
Liege-54 B.1.221 24.93 27.67 26.44 25.68 
Liege-55 B.1 25.05 29.84 28.51 27.44 
Liege-56 B.1.221 25.55 28.6 26.82 24.72 
Liege-57 B.1.177 27.55 32.21 27.35 21.38 




















etect viruses with the 242–244 deletion, in multiplex with the 
etection of the UK 501 V.V1 variant and the standard detection 
f SARS-CoV-2 N1/N2 genes proposed by the centre for Disease 
ontrol and Prevention (CDC) ( Table 2 ) . No amplification was 
bserved for any 501 V.V2 samples, while all other SARS-CoV-2 
irusesincluding 501 V.V1 and 501 V.V3 samples were amplified. 
oncerningsensitivity of this multiplex RT-qPCR,fifty-eight infected 
amples with Cycle threshold (Ct) values ranging from 7.78 to 
1.25 for the N1/N2 genes were tested and they were properly 
etected by the 242/244del primer/probe set with a mean delay e20 f 3.78Ct values compared to the standard N1/N2 genes detection 
see Table 2 ).Sensitivity limit of themethod was also assessed 
nd samples were properly amplified down to 100 viral copies 
er ml. Testing samples below this threshold could lead to false 
rop-out results.Moreover, this method could potentially detect 
ther viruses with the 242/244 LLA deletion. 
Our multiplex RT-qPCRcan thus serve as a screening assay 
o prioritize samples presenting the 242/244 LLA deletion for 
equencing and to confirm their identification as the emerging 
01 V.V2 lineage. 
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